Bayer AG (BAYRY) announced that the first patient has been enrolled in the late-stage SOHO-02 study on pipeline candidate BAY 292708.BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR) with high selectivity for mutant versus wild-type EGFR.The phase III SOHO-02 study is an open-label, randomized, multice ...